{"id":"W4250306919","doi":"10.1200/jco.2013.31.4_suppl.lba445","title":"Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Internal medicine; Neutropenia; Bevacizumab; Clinical endpoint; Placebo; Colorectal cancer; Pegfilgrastim; Febrile neutropenia; Gastroenterology; Regimen; Surgery; Oncology; Randomized controlled trial; Chemotherapy; Irinotecan; Oxaliplatin; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002490914,0.001752744,0.002781417,0.0003911018,0.000631663,0.00113137,0.0008127011,0.002467934,0.009401073],"category_scores_gemma":[0.003159261,0.0007915402,0.001523488,0.0003680061,0.00116325,0.001140712,0.0004208724,0.003577414,0.001251737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007821292,"about_ca_system_score_gemma":0.001617679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006488693,"about_ca_topic_score_gemma":0.001713385,"domain_scores_codex":[0.9991668,0.0004784063,0.00006287258,0.0001338155,0.00004975187,0.0001082938],"domain_scores_gemma":[0.9982861,0.0004661793,0.0004200344,0.000109305,0.0001075713,0.0006108115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.985628,0.005953562,0.0003505806,0.0002704366,0.0004292296,0.00002286537,0.00002704401,0.0001426603,0.001187721,0.0000382636,0.0005216505,0.005427883],"study_design_scores_gemma":[0.9605401,0.0379543,0.0007131632,0.00001418056,0.0002338322,0.00001258106,0.000005689857,0.0001053319,0.000133882,0.0000514739,0.0002307653,0.000004752829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733306,0.003932781,0.001010449,0.001282909,0.00075796,0.0129111,0.00268839,0.0002160237,0.003869821],"genre_scores_gemma":[0.9791781,0.00172542,0.001662914,0.001469716,0.0004283857,0.01048752,0.001748001,0.00002598456,0.003273954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009401073,"threshold_uncertainty_score":0.03144974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1036474043815489,"score_gpt":0.4599664402436699,"score_spread":0.356319035862121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}